FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

$\sim$	AΡ	ᇚ	A١	/ N I

OMB Number:	3235-0287
Estimated average burden	1
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PENDARVIS DAVID			2. Issuer Name <b>and</b> Ticker or Trading Symbol RESMED INC [ RMD ]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owne				
(Last) (First) (Middle) RESMED INC.		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/03/2020	X	Officer (give title below)  Chief Administrative	Other (specify below) Officer			
9001 SPECTRUM CENTER BLVD.  (Street)  SAN DIEGO CA 92123		92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	dual or Joint/Group Filing (Cher Form filed by One Reporting Form filed by More than One	Person			
(City)	(State)	(Zip)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities A Of (D) (Instr. 3,		A) or Disposed	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)
ResMed Common Stock	11/03/2020		<b>M</b> <sup>(1)</sup>		5,918	A	\$57.76	142,046	D	
ResMed Common Stock	11/03/2020		<b>S</b> <sup>(1)</sup>		5,918	D	\$201.1429(2)	136,128	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (In	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$57.76	11/03/2020		М			5,918	11/11/2017 <sup>(3)</sup>	11/16/2023	ResMed Common Stock	5,918	\$0	0	D	

## Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan.
- $2. This transaction was executed in multiple trades at prices ranging from \$197.28 \ to \ 203.32. The price reported above reflects the weighted average sale price.$
- 3. Represents date options first became exercisable. Options vest 1/3 per year.

David Pendarvis, Chief Administrative Officer

\*\* Signature of Reporting Person Date

11/05/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.